School of Medical Sciences, University of Adelaide, South Australia, Australia.
Curr Opin Support Palliat Care. 2013 Jun;7(2):162-7. doi: 10.1097/SPC.0b013e32835ec861.
Tyrosine kinase inhibitors (TKIs) are increasingly common treatments for cancer; however, their effective use is hampered by unwanted side effects. One of the most common of these is TKI-induced diarrhea, although so far very little is known about its mechanisms and the best management approaches. As such, this review will briefly cover the extent of the problem, models for researching the problem and touch on future directions for management approaches to the problem.
As there is a paucity of knowledge regarding the mechanisms of TKI-induced diarrhea in humans, this review will discuss the rodent models that have been used in the investigation of TKI-induced gut injury. This will be put into context with the pharmacological targets of TKIs and how this new information might help to better tailor treatment and management of patients on these drugs.
The recognition of TKI-induced diarrhea as a significant treatment side effect has prompted efforts into uncovering the pathogenesis of this complication. This will enable future patients to be better managed throughout their treatment with these highly effective cancer drugs.
酪氨酸激酶抑制剂（TKI）在癌症治疗中越来越常见；然而，其使用受到不良反应的阻碍。其中最常见的不良反应之一是 TKI 诱导的腹泻，尽管目前对其机制和最佳管理方法知之甚少。因此，本综述将简要介绍该问题的严重程度、研究该问题的模型，并探讨该问题管理方法的未来方向。
由于人类对 TKI 诱导性腹泻的机制知之甚少，本综述将讨论用于研究 TKI 诱导性肠道损伤的啮齿动物模型。这将结合 TKI 的药理学靶点进行讨论，以及这些新信息如何有助于更好地调整接受这些药物治疗的患者的治疗和管理。
TKI 诱导性腹泻作为一种严重的治疗副作用已引起人们的关注，促使人们努力揭示这种并发症的发病机制。这将使未来的患者在接受这些高效癌症药物治疗时得到更好的管理。
